Antiarrhythmic drugs for atrial fibrillation

Bibliography

• Camm AJ, Kirchhof P, Lip GY, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology. Eur Heart J 2010;31(19):2369-429
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285(18):2370-75
   Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33
   PubMed Web of Science ®Google Scholar
• Roy D, Talajic M, Nattel S, Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77
   PubMed Web of Science ®Google Scholar
• Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 2008;10(6):647-65
   Google Scholar
• Singh BN. Amiodarone as paradigm for developing new drugs for atrial fibrillation. J Cardiovasc Pharmacol 2008;52:300-5
   PubMed Web of Science ®Google Scholar
• Singh D, Cingolani E, Diamond GA, Kaul S. Dronedarone for atrial fibrillation. Have we expanded the antiarrhythmic armamentarium? J Am Coll Cardiol 2010;55:1569-76
   PubMed Web of Science ®Google Scholar
• Ehrlich JR, Biliczki P, Hohnloser SH, Nattel S. Atrial-selective approaches for the treatment of atrial fibrillation. J Am Coll Cardiol 2008;51:787-92
   Google Scholar
• Wettwer E, Hala O, Christ T, Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 2004;110:2299-306
   PubMed Web of Science ®Google Scholar
• Burashnikov A, DiDiego JM, Zygmunt AC, Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007;116:1449-57
   PubMed Web of Science ®Google Scholar
• Fedida D, Orth PM, Chen JY, The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2005;16:1227-38
   PubMed Web of Science ®Google Scholar
• Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008;1:62-73
   PubMed Web of Science ®Google Scholar
• Joglar JA, Kowal RC. Electrical cardioversion of atrial fibrillation. Cardiol Clin 2004;22:101-11
   Google Scholar
• Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2007;4:CD005049
   Google Scholar
• Yang F, Hanon S, Lam P, Schweitzer P. Quinidine revisited. Am J Med 2009;122(4):317-21
   Google Scholar
• Fetsch T, Bauer P, Engberding R, Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004;25:1385-94
   PubMed Web of Science ®Google Scholar
• Patten M, Maas R, Bauer P, Suppression of paroxysmal atrial tachyarrhythmias-results of the SOPAT trial. Eur Heart J 2004;25:1395-404
   PubMed Web of Science ®Google Scholar
• Coplen SE, Antman EM, Berlin JA, Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990;82(4):1106-16
   Google Scholar
• Karlson BW, Torstensson I, Abjorn C, Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 1988;9:284-90
   PubMedGoogle Scholar
• Crijns HJ, Gosselink AT, Lie KI. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. Cardiovasc Drugs Ther 1996;10:145-52
   PubMedGoogle Scholar
• Kochiadakis GE, Igoumenidis NE, Solomou MC, Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion. Cardiovasc Drugs Ther 1998;12(1):75-81
   Google Scholar
• Volgman AS, Carberry PA, Stambler B, Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998;31:1414-19
   PubMed Web of Science ®Google Scholar
• Kochiadakis GE, Igoumenidis NE, Hamilos ME, A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation. Am J Cardiol 2007;99:1721-5
   PubMed Web of Science ®Google Scholar
• Capucci A, Lenzi T, Boriani G, Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992;70:69-72
   PubMed Web of Science ®Google Scholar
• Donovan KD, Dobb GJ, Coombs LJ, Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide. Am J Cardiol 1991;67(2):137-41
   Google Scholar
• Alp NJ, Bell JA, Shahi M. Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. Heart 2000;84:37-40
   PubMedGoogle Scholar
• Reisinger J, Gatterer E, Lang W, Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J 2004;25:1318-2437
   PubMed Web of Science ®Google Scholar
• Reisinger J, Gatterer E, Heinze G, Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998;81:1450-4
   PubMed Web of Science ®Google Scholar
• Anderson JL, Gilbert EM, Alpert BL, Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 1989;80:1557-70
   PubMed Web of Science ®Google Scholar
• Pietersen AH, Hellemann H. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. Am J Cardiol 1991;67:713-17
   PubMedGoogle Scholar
• Naccarelli GV, Dorian P, Hohnloser SH, Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. Am J Cardiol 1996;77:53A-59A
   PubMed Web of Science ®Google Scholar
• Chimienti M, Cullen MT Jr, Casadei G. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Eur Heart J 1995;16(12):1943-51
   Google Scholar
• van Gelder IC, Crijns HJ, van Gilst WH, Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989;64:1317-21
   PubMedGoogle Scholar
• Echt DS, Liebson PR, Mitchell LB, The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324(12):781-8
   Google Scholar
• Fresco C, Proclemer A, Pavan A, Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. Clin Cardiol 1996;19(5):409-12
   Google Scholar
• Ganau G, Lenzi T. Intravenous propafenone for converting recent onset atrial fibrillation in emergency departments: a randomized placebo-controlled multicenter trial. FAPS Investigators Study Group. J Emerg Med 1998;16(3):383-7
   Google Scholar
• Boriani G, Martignani C, Biffi M, Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a comparison review on in-hospital treatment. Drugs 2002;62(3):415-23
   Google Scholar
• Botto GL, Bonini W, Broffoni T, Randomized, crossover, controlled comparison of oral loading versus intravenous infusion of propafenone in recent-onset atrial fibrillation. Pacing Clin Electrophysiol 1998;21(11 Pt 2):2480-4
   Google Scholar
• Capucci A, Boriani G, Rubino I, Conversion of recent onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol 1994;74:503-5
   PubMedGoogle Scholar
• Blanc JJ, Voinov C, Maarek M. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group. Am J Cardiol 1999;84:1029-32
   PubMed Web of Science ®Google Scholar
• Capucci A, Boriani G, Rubino I, A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol 1994;43:305-1352
   PubMed Web of Science ®Google Scholar
• UK Propafenone PSVT Study Group. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 1995;92:2550-7
   PubMedGoogle Scholar
• Aliot E, Denjoy I. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Am J Cardiol 1996;77(3):66A-71A
   Google Scholar
• Kochiadakis GE, Igoumenidis NE, Hamilos ME, Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. Am J Cardiol 2004;94(12):1563-6
   Google Scholar
• Bellandi F, Simonetti I, Leoncini M, Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol 2001;88(6):640-5
   Google Scholar
• Lee SH, Chen SA, Chiang CE, Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. J Intern Med 1996;239:253-60
   PubMedGoogle Scholar
• Singh BN, Singh SN, Reda DJ, Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-72
   PubMed Web of Science ®Google Scholar
• Benditt DG, Williams JH, Jin J, Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1999;84:270-7
   PubMed Web of Science ®Google Scholar
• Reimold SC, Cantillon CO, Friedman PL, Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71:558-63
   PubMed Web of Science ®Google Scholar
• Drew BJ, Ackerman MJ, Funk M, Prevention of torsade de pointes in hospital settings. A scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010;121:1047-60
   PubMed Web of Science ®Google Scholar
• Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 1990;65:74A-81A
   PubMed Web of Science ®Google Scholar
• Ellenbogen KA, Stambler BS, Wood MA, Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996;28:130-6
   PubMed Web of Science ®Google Scholar
• Stambler BS, Wood MA, Ellenbogen KA, Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-21
   PubMed Web of Science ®Google Scholar
• Kafkas NV, Patsilinakos SP, Mertzanos GA, Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. Int J Cardiol 2007;118(3):321-5
   Google Scholar
• Hongo RH, Themistoclakis S, Raviele A, Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. J Am Coll Cardiol 2004;44:864-57
   PubMed Web of Science ®Google Scholar
• Glatter K, Yang Y, Chatterjee K, Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation 2001;103(2):253-7
   Google Scholar
• Fragakis N, Bikias A, Delithanasis I, Acute beta-adrenoceptor blockade improves efficacy of ibutilide in conversion of atrial fibrillation with a rapid ventricular rate. Europace 2009;11(1):70-4
   Google Scholar
• Patsilinakos S, Christou A, Kafkas N, Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent. Am J Cardiol 2010;106(5):673-6
   Google Scholar
• Singh S, Zoble RG, Yellen L, Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000;102:2385-90
   PubMed Web of Science ®Google Scholar
• Greenbaum RA, Campbell TJ, Channer KS, Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) study [abstract]. Circulation 1998;98(Suppl): I-633
   Google Scholar
• Pedersen OD, Bagger H, Keller N, Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) sub-study. Circulation 2001;104(3):292-6
   Google Scholar
• Bianconi L, Castro A, Dinelli M, Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J 2000;21(15):1265-73
   Google Scholar
• Torp-Pedersen C, Moller M, Block-Thomsen PE, Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341(12):857-65
   Google Scholar
• Kober L, Bloch Thomsen PE, Moller M, Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 2000;356(9247):2052-8
   Google Scholar
• Grossman M, Dobrev D, Kirch W. Amiodarone causes endothelium-dependent vasodilation in human hand veins in vivo. Clin Pharmacol Ther 1998;64:302-11
   Google Scholar
• Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. Circulation 2003;107:1440-6
   Google Scholar
• Boriani G, Diemberger I, Biffi M, Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs 2004;64(24):2741-629
   Google Scholar
• Vardas PE, Kochiadakis GE, Igoumenidis NE, Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest 2000;117(6):1538-45
   Google Scholar
• Xanthos T, Bassiakou E, Vlachos IS, Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration. Int J Cardiol 2007;121(3):291-5
   Google Scholar
• Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000;86:950-3
   PubMed Web of Science ®Google Scholar
• Kerin NZ, Faitel K, Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. Arch Intern Med 1996;156(1):49-5372
   Google Scholar
• Singh SN, Fletcher RD, Fisher SG, Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: survival trial of antiarrhythmic therapy in congestive heart failure. N Engl J Med 1995;333:77-82
   PubMed Web of Science ®Google Scholar
• Julian DG, Camm AJ, Frangin G, Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349:667-74
   PubMed Web of Science ®Google Scholar
• Kochiadakis GE, Igoumenidis NE, Solomou MC, Efficacy of amiodarone for the termination of persistent atrial fibrillation. Am J Cardiol 1999;83:58-61
   PubMedGoogle Scholar
• Dronedarone Label. Rockville, MD: Food and Drug Administration, 2009. Available from: www.fda.gov. [Accessed 30 December 2010]
   Google Scholar
• Singh BN, Connolly SJ, Crijns HJ, ; for the EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357:987-99
   PubMed Web of Science ®Google Scholar
• Davy JM, Herold M, Hoglund C, Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO) study. Am Heart J 2008;156:527. e1-9
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, McMurray JJ, Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Crijns HJ, van Eickels M, ; for the ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78
   PubMed Web of Science ®Google Scholar
• Le Heuzey JY, De Ferrari GM, Radzik D, A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010;21(6):597-605
   Google Scholar
• Connolly SJ, Crijns HJ, Torp-Pedersen C, Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009;120(13):1174-80
   Google Scholar
• Tschuppert Y, Buclin T, Rothuizen LE, Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007;64(6):785-91
   Google Scholar
• Orth PM, Hesketh JC, Mak CK, RSD1235 blocks late INa and suppresses early afterdepolarization and torsades de pointes induced by class III agents. Cardiovasc Res 2006;70:486-96
   PubMed Web of Science ®Google Scholar
• Roy D, Rowe BH, Stiell IG, A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004;44:2355-61
   PubMed Web of Science ®Google Scholar
• Roy D, Pratt CM, Torp-Pedersen C, Vernakalant hydrochloride for rapid conversion of atrial fibrillation. A phase 3, randomized, placebo-controlled trial. Circulation 2008;117:1518-25
   PubMed Web of Science ®Google Scholar
• Pratt CM, Roy D, Torp-Pedersen C, Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol 2010;106(9):1277-83
   Google Scholar
• Kowey PR, Dorian P, Mitchell LB, ; for the Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2:652-59
   PubMed Web of Science ®Google Scholar
• Camm AJ, Capucci A, Hohnloser S, Clinical efficacy and safety of vernakalant compared with amiodarone for intravenous conversion of recent onset atrial fibrillation. Heart Rhythm Society 2010 Scientific Sessions; May 14 2010; Denver, CO
   Google Scholar
• Cardiome Pharma Corp. Available from: http://www.cardiome.com/VernakalantOral.php. [Accessed 10 December 2010]
   Google Scholar
• A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF) (ACT V). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00989001 [Last accessed 10 November 2010]
   Google Scholar
• Antzelevitch C, Belardinelli L, Zygmunt AC, Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110:904-10
   PubMed Web of Science ®Google Scholar
• Scirica BM, Morrow DA, Hod H, Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116(15):1647-52
   PubMed Web of Science ®Google Scholar
• Murdock DK, Kersten M, Kaliebe J, The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible “pill in the pocket” approach to atrial fibrillation. Indian Pacing Electrophysiol J 2009;9:260-67
   PubMedGoogle Scholar
• Murdock DK, Overton N, Kersten M, The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J 2008;8:175-81
   PubMedGoogle Scholar
• Burashnikov A, Sicouri S, Di Diego JM, Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol 2010;56(15):1216-24
   Google Scholar
• Alboni P, Botto GL, Baldi N, Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med 2004;351:2384-91
   PubMed Web of Science ®Google Scholar
• Alboni P, Botto GL, Boriani G, Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during ‘pill-in-the-pocket’ treatment. Heart 2010;96(7):546-9
   Google Scholar
• Page RL, Kerber RE, Russell JK, Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol 2002;39:1956-63
   Google Scholar
• Van Gelder IC, Groenveld HF, Crijns HJ, Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-73
   PubMed Web of Science ®Google Scholar